Income Statement Celltrion, Inc.

Equities

A068270

KR7068270008

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 16/01/2026			5-day change	1st Jan Change
209,000.00 ^KRW	-0.71%		-3.69%	+15.47%

01-14	Celltrion Presents Innovative Drug Pipeline and U.S. Manufacturing and R&D Expansion Strategy At the 44Th Annual J.P. Morgan Healthcare Conference	CI
01-06	Abpro, Celltrion Say Solid Cancer Tumor Therapy Investigational New Drug Application Receives US FDA Clearance	MT

954da623359d6dd5bc5209126c06f98.HkQCzmP6_zf-lOT4m0nEtG66rkKWD06ZH4NyPJLyV9s.XXVgiCCrjlG5ude5zSGb3hvJ2AGuYwLtS-FAVte1NKN2CXG5NpOzTb_A1A

Published financial data: CELLTRION, INC.

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: December	2020	2021	2022	2023	2024
Revenues	1,849B	1,912B	2,284B	2,176B	3,557B
Other Revenues, Total	-110	-30	-10	-10	-10
Total Revenues	1,849B	1,912B	2,284B	2,176B	3,557B
Cost of Goods Sold, Total	821B	806B	1,251B	1,125B	1,876B
Gross Profit	1,028B	1,106B	1,033B	1,052B	1,682B
Selling General & Admin Expenses, Total	127B	186B	205B	203B	750B
Provision for Bad Debts	-1.69M	14.31M	-1.69M	-5.03B	1.03B
R&D Expenses	171B	126B	140B	161B	200B
Depreciation & Amortization - (IS)	3.19B	2.8B	3.46B	5.35B	12.92B
Amortization of Goodwill and Intangible Assets - (IS)	7.84B	34.25B	37.35B	35.61B	161B
Other Operating Expenses	-	-	-	-	64.9B
Other Operating Expenses, Total	309B	349B	385B	400B	1,190B
Operating Income	719B	757B	647B	651B	492B
Interest Expense, Total	-7.5B	-8.24B	-7.51B	-9.67B	-75.57B
Interest And Investment Income	5.72B	4.4B	14.22B	19.06B	33.53B
Net Interest Expenses	-1.78B	-3.84B	6.71B	9.4B	-42.04B
Income (Loss) On Equity Invest.	2.59B	-4.97B	7.35B	-12.68B	-3.43B
Currency Exchange Gains (Loss)	-22.74B	32.91B	16.99B	11.62B	144B
Other Non Operating Income (Expenses)	-41.98B	-6.31B	-41.41B	355M	-1.54B
EBT, Excl. Unusual Items	655B	775B	637B	660B	589B
Gain (Loss) On Sale Of Investments	15.62B	1.15B	-	1.51B	80.47M
Gain (Loss) On Sale Of Assets	-8.86B	32.88B	828M	13.35B	4.07B
Asset Writedown	-4.27B	-57.35B	-11.49B	-3.88B	-16.92B
Other Unusual Items	-	-	-	-	-
EBT, Incl. Unusual Items	657B	751B	626B	671B	576B
Income Tax Expense	131B	156B	94.83B	131B	157B
Earnings From Continuing Operations	526B	596B	531B	540B	419B
Earnings Of Discontinued Operations	-	-	11.22B	-	-
Net Income to Company	526B	596B	543B	540B	419B
Minority Interest	-7.94B	-16.31B	-4.73B	-4.06B	3.81B
Net Income - (IS)	518B	579B	538B	536B	423B
Net Income to Common Incl Extra Items	518B	579B	538B	536B	423B
Net Income to Common Excl. Extra Items	518B	579B	527B	536B	423B
Per Share Items
Net EPS - Basic	3.28K	3.66K	3.43K	3.44K	1.88K
Basic EPS - Continuing Operations	3.28K	3.66K	3.36K	3.44K	1.88K
Basic Weighted Average Shares Outstanding	158M	158M	157M	156M	225M
Net EPS - Diluted	3.22K	3.62K	3.42K	3.44K	1.87K
Diluted EPS - Continuing Operations	3.22K	3.62K	3.35K	3.44K	1.87K
Diluted Weighted Average Shares Outstanding	159M	159M	157M	156M	226M
Normalized Basic EPS	2.54K	2.96K	2.51K	2.63K	1.65K
Normalized Diluted EPS	2.53K	2.94K	2.5K	2.62K	1.65K
Dividend Per Share	-	647.45	330.2	457.88	686.81
Payout Ratio	-	0	19.05	9.64	24.51
Supplemental Items
EBITDA	892B	971B	874B	897B	910B
EBITA	835B	909B	809B	833B	838B
EBIT	719B	757B	647B	651B	492B
EBITDAR	893B	971B	874B	898B	-
Effective Tax Rate - (Ratio)	20	20.7	15.14	19.58	27.29
Total Current Taxes	-	-	-	-	-
Total Deferred Taxes	-	-	-	-	-
Normalized Net Income	401B	468B	393B	409B	372B
Interest Capitalized	-	8.13B	16.38B	32.62B	20.69B
Supplemental Operating Expense Items
Advertising Expense	5.25B	12.77B	15.09B	17.33B	93.56B
Selling and Marketing Expenses	32.85B	53.4B	59.67B	76.92B	379B
General and Administrative Expenses	8.01B	22.8B	3.3B	7.23B	8.93B
Research And Development Expense From Footnotes	171B	126B	140B	161B	200B
Net Rental Expense, Total	279M	337M	345M	370M	-
Imputed Operating Lease Interest Expense	26.38M	-	-	-	-
Imputed Operating Lease Depreciation	253M	-	-	-	-
Stock-Based Comp., SG&A Exp. (Total)	8.52B	9.46B	11.23B	11.98B	26.84B
Total Stock-Based Compensation	8.52B	9.46B	11.23B	11.98B	26.84B

Fiscal Period: December	2020	2021	2022	2023	2024
Assets
Cash And Equivalents	684B	1,188B	551B	565B	996B
Short Term Investments	14.03B	31.58B	43.28B	193B	147B
Trading Asset Securities, Total	-	-	-	-	-
Total Cash And Short Term Investments	698B	1,220B	594B	757B	1,143B
Accounts Receivable, Total	1,252B	1,101B	1,622B	939B	1,215B
Other Receivables	63.32B	20.82B	13.15B	8.82B	43.7B
Notes Receivable	0	42.47B	19.05B	1.25B	1.13B
Total Receivables	1,316B	1,164B	1,654B	949B	1,260B
Inventory	384B	578B	616B	3,041B	2,766B
Prepaid Expenses	10.2B	11.3B	13.43B	17.77B	25.12B
Other Current Assets, Total	108B	101B	51.46B	115B	390B
Total Current Assets	2,516B	3,074B	2,930B	4,881B	5,584B
Gross Property Plant And Equipment	1,359B	1,423B	1,544B	1,816B	1,710B
Accumulated Depreciation	-412B	-473B	-537B	-602B	-466B
Net Property Plant And Equipment	946B	950B	1,007B	1,215B	1,245B
Long-term Investments	79.37B	89.28B	118B	135B	161B
Goodwill	62.92B	33.01B	35.16B	11,475B	11,914B
Other Intangibles, Total	275B	287B	265B	502B	390B
Accounts Receivable Long-Term	0	0	62.89B	0	0
Loans Receivable Long-Term	0	0	131M	131M	247M
Deferred Tax Assets Long-Term	28.99B	28.62B	32.18B	63.47B	194B
Deferred Charges Long-Term	1,066B	1,172B	1,322B	1,358B	1,398B
Other Long-Term Assets, Total	44.8B	39.77B	119B	287B	170B
Total Assets	5,020B	5,674B	5,892B	19,918B	21,055B
Liabilities
Accounts Payable, Total	33.96B	80.72B	50.27B	50.85B	75.31B
Accrued Expenses, Total	131B	139B	157B	187B	150B
Short-term Borrowings	437B	512B	554B	1,608B	1,989B
Current Portion of Long-Term Debt	132B	54.48B	81.43B	168B	86.2B
Current Portion of Leases	2.42B	3.01B	2.73B	8.17B	11.67B
Current Income Taxes Payable	100B	180B	88.7B	57.04B	218B
Unearned Revenue Current, Total	3.43B	3.58B	6.77B	21.71B	18.18B
Other Current Liabilities	216B	238B	353B	370B	638B
Total Current Liabilities	1,057B	1,210B	1,294B	2,471B	3,187B
Long-Term Debt	200B	170B	152B	99.13B	86.6B
Long-Term Leases	3.09B	4.37B	2.89B	7.98B	19.09B
Unearned Revenue Non Current	31.25B	28.23B	23.01B	77.4B	73.49B
Pension & Other Post Retirement Benefits	-	-	3.35B	-	-
Deferred Tax Liability Non Current	86.21B	21.58B	1.11B	120B	99.26B
Other Non Current Liabilities	215B	189B	141B	17.1B	9.6B
Total Liabilities	1,593B	1,624B	1,617B	2,792B	3,475B
Common Stock, Total	135B	138B	141B	220B	221B
Additional Paid In Capital	828B	856B	871B	14,790B	14,828B
Retained Earnings	2,475B	3,052B	3,485B	3,964B	3,744B
Treasury Stock	-192B	-226B	-502B	-2,204B	-2,108B
Comprehensive Income and Other	61.49B	96.23B	144B	211B	754B
Total Common Equity	3,308B	3,917B	4,139B	16,981B	17,439B
Minority Interest	120B	133B	135B	145B	141B
Total Equity	3,428B	4,050B	4,274B	17,126B	17,580B
Total Liabilities And Equity	5,020B	5,674B	5,892B	19,918B	21,055B
Supplemental Items
ECS Total Shares Outstanding on Filing Date	158M	158M	156M	226M	224M
ECS Total Common Shares Outstanding	158M	158M	156M	226M	224M
Book Value / Share	20.92K	24.75K	26.45K	75.05K	77.9K
Tangible Book Value	2,970B	3,598B	3,839B	5,003B	5,135B
Tangible Book Value Per Share	18.79K	22.73K	24.53K	22.11K	22.94K
Total Debt	774B	744B	792B	1,890B	2,193B
Net Debt	76.07B	-476B	198B	1,133B	1,050B
Debt Equivalent Oper. Leases	2.23B	2.69B	2.76B	2.96B	-
Minority Interest, Total (Incl. Fin. Div)	120B	133B	135B	145B	141B
Equity Method Investments, Total	48.03B	64.84B	88.54B	105B	112B
Account Code - Inventory Valuation	-	-	-	-	-
Inventories - Raw Materials, Total	187B	245B	295B	279B	330B
Inventories - Work In Process, Total	26.62B	39.7B	48.31B	78.63B	103B
Inventories - Finished Goods, Total	195B	359B	365B	2,727B	2,386B
Inventories - Others	904M	2.2B	11.51B	10.2B	13.37B
Land - (BS)	302B	302B	302B	302B	302B
Buildings, Total	372B	373B	373B	601B	601B
Machinery, Total	630B	684B	700B	723B	724B
Accumulated Allowance for Doubtful Accounts (Supple)	1.07B	1.36B	1.53B	313M	2.48B

Fiscal Period: December	2020	2021	2022	2023	2024
Net Income	518B	579B	538B	536B	423B
Depreciation & Amortization - CF	57.66B	61.96B	64.72B	63.78B	72.61B
Amortization of Goodwill and Intangible Assets - (CF)	116B	152B	162B	182B	346B
Depreciation & Amortization, Total	174B	214B	226B	246B	418B
Amortization of Deferred Charges, Total - (CF)	-	-	-	-	-
(Gain) Loss From Sale Of Asset	180M	-23.92B	880M	-1.96B	-44.16B
(Gain) Loss on Sale of Investments - (CF)	-6.94B	-10B	-838M	-12.83B	56.79B
Asset Writedown & Restructuring Costs	4.27B	57.23B	10.62B	3.82B	151M
(Income) Loss On Equity Investments - (CF)	-2.59B	4.97B	-15.68B	12.68B	3.43B
Stock-Based Compensation (CF)	20.22B	22.05B	25.73B	27.77B	45.22B
Provision and Write-off of Bad Debts	323M	-235M	7.51B	-5.08B	1.03B
Other Operating Activities, Total	151B	67.83B	-43.44B	-47.3B	19.81B
Change In Accounts Receivable	-537B	109B	-683B	-296B	-174B
Change In Inventories	-130B	-268B	-215B	57.25B	225B
Change In Accounts Payable	-7.85B	44.08B	53.57B	-2.19B	-144B
Change in Other Net Operating Assets	167B	114B	96.19B	19.53B	72.18B
Cash from Operations	351B	911B	864M	537B	902B
Capital Expenditure	-87.01B	-63.38B	-111B	-210B	-135B
Sale of Property, Plant, and Equipment	3.16B	13.42M	3.46M	11.51M	38.76M
Cash Acquisitions	-	-	-3.49B	374B	-28.69B
Divestitures	-	-	17.49B	-	-
Sale (Purchase) of Intangible assets	-453B	-230B	-201B	-141B	-195B
Investment in Marketable and Equity Securities, Total	58.13B	-57.03B	-39.37B	-186B	-30.38B
Other Investing Activities, Total	6.62B	-5.07B	40.29B	23.55B	220B
Cash from Investing	-472B	-356B	-297B	-139B	-169B
Short Term Debt Issued, Total	-	-	-	-	-
Long-Term Debt Issued, Total	439B	207B	181B	828B	2,137B
Total Debt Issued	439B	207B	181B	828B	2,137B
Short Term Debt Repaid, Total	-	-	-	-	-
Long-Term Debt Repaid, Total	-162B	-243B	-135B	-206B	-1,891B
Total Debt Repaid	-162B	-243B	-135B	-206B	-1,891B
Issuance of Common Stock	19.4B	21.49B	9.86B	7.36B	21.13B
Repurchase of Common Stock	-15.87B	-39.13B	-281B	-919B	-439B
Common Dividends Paid	-	-	-	-	-
Common & Preferred Stock Dividends Paid	-	-3.78M	-102B	-51.66B	-104B
Common & Preferred Stock Dividends Paid	-	-3.78M	-102B	-51.66B	-104B
Other Financing Activities, Total	-14.88B	-16.04B	-22.7B	-43.95B	-77.72B
Cash from Financing	266B	-69.28B	-350B	-385B	-353B
Foreign Exchange Rate Adjustments	-6.6B	17.98B	9.27B	246M	52.38B
Miscellaneous Cash Flow Adjustments	-	-	-	-	-
Net Change in Cash	138B	504B	-637B	13.43B	432B
Supplemental Items
Cash Interest Paid	14.87B	16.02B	22.67B	41.77B	75.22B
Cash Income Tax Paid (Refund)	64.44B	136B	217B	154B	145B
Levered Free Cash Flow	-394B	517B	-140B	-1,449B	513B
Unlevered Free Cash Flow	-389B	522B	-135B	-1,443B	560B
Change In Net Working Capital	480B	-119B	465B	1,757B	-138B
Net Debt Issued / Repaid	277B	-35.59B	45.62B	622B	246B

Fiscal Period: December	2020	2021	2022	2023	2024
Profitability
Return on Assets	10.12	8.85	6.99	3.16	1.5
Return on Total Capital	11.87	10.52	8.2	3.38	1.59
Return On Equity %	16.69	15.93	12.77	5.04	2.41
Return on Common Equity	17.07	16.04	13.07	5.07	2.46
Margin Analysis
Gross Profit Margin %	55.58	57.85	45.22	48.33	47.27
SG&A Margin	6.85	9.74	8.97	9.34	21.08
EBITDA Margin %	48.26	50.8	38.25	41.23	25.59
EBITA Margin %	45.14	47.55	35.41	38.3	23.55
EBIT Margin %	38.86	39.59	28.34	29.93	13.83
Income From Continuing Operations Margin %	28.43	31.17	23.26	24.8	11.78
Net Income Margin %	28	30.31	23.55	24.61	11.88
Net Avail. For Common Margin %	28	30.31	23.06	24.61	11.88
Normalized Net Income Margin	21.7	24.47	17.22	18.77	10.45
Levered Free Cash Flow Margin	-21.28	27.04	-6.13	-66.58	14.42
Unlevered Free Cash Flow Margin	-21.03	27.31	-5.92	-66.31	15.75
Asset Turnover
Asset Turnover	0.42	0.36	0.39	0.17	0.17
Fixed Assets Turnover	1.98	2.02	2.33	1.96	2.89
Receivables Turnover (Average Receivables)	1.79	1.62	1.68	1.7	3.3
Inventory Turnover (Average Inventory)	2.38	1.67	2.1	0.61	0.65
Short Term Liquidity
Current Ratio	2.38	2.54	2.26	1.98	1.75
Quick Ratio	1.91	1.93	1.72	0.69	0.75
Operating Cash Flow to Current Liabilities	0.33	0.75	0	0.22	0.28
Days Sales Outstanding (Average Receivables)	204.54	224.69	217.58	214.75	110.83
Days Outstanding Inventory (Average Inventory)	153.95	217.96	174.21	593.61	566.36
Average Days Payable Outstanding	15.6	20.94	18.54	5.2	14.4
Cash Conversion Cycle (Average Days)	342.88	421.71	373.25	803.16	662.78
Long Term Solvency
Total Debt/Equity	22.59	18.38	18.54	11.04	12.47
Total Debt / Total Capital	18.43	15.52	15.64	9.94	11.09
LT Debt/Equity	5.92	4.31	3.61	0.63	0.6
Long-Term Debt / Total Capital	4.83	3.64	3.05	0.56	0.53
Total Liabilities / Total Assets	31.72	28.62	27.45	14.02	16.5
EBIT / Interest Expense	95.77	91.88	86.21	67.4	6.51
EBITDA / Interest Expense	118.94	117.87	116.36	92.83	12.04
(EBITDA - Capex) / Interest Expense	107.34	110.18	101.55	71.1	10.26
Total Debt / EBITDA	0.87	0.77	0.91	2.11	2.41
Net Debt / EBITDA	0.09	-0.49	0.23	1.26	1.15
Total Debt / (EBITDA - Capex)	0.96	0.82	1.04	2.75	2.83
Net Debt / (EBITDA - Capex)	0.09	-0.52	0.26	1.65	1.35
Growth Over Prior Year
Total Revenues, 1 Yr. Growth %	63.86	3.38	20.63	-4.71	63.45
Gross Profit, 1 Yr. Growth %	62.22	7.6	-5.05	1.86	59.88
EBITDA, 1 Yr. Growth %	66.73	8.8	-8.84	2.71	1.45
EBITA, 1 Yr. Growth %	71.44	8.9	-9.76	3.04	0.5
EBIT, 1 Yr. Growth %	88.34	5.32	-13.03	0.65	-24.47
Earnings From Cont. Operations, 1 Yr. Growth %	74.4	13.33	-9.3	1.57	-22.39
Net Income, 1 Yr. Growth %	72	11.92	-7.18	-0.41	-21.09
Normalized Net Income, 1 Yr. Growth %	69.29	16.6	-14.48	3.87	-8.97
Diluted EPS Before Extra, 1 Yr. Growth %	71.51	12.42	-6.46	2.6	-45.51
Accounts Receivable, 1 Yr. Growth %	53.79	-12.08	47.3	-42.09	29.4
Inventory, 1 Yr. Growth %	25.31	50.41	6.62	393.46	-8.98
Net Property, Plant and Equip., 1 Yr. Growth %	2.46	0.44	5.96	20.61	2.47
Total Assets, 1 Yr. Growth %	30.07	13.03	3.83	238.06	5.5
Tangible Book Value, 1 Yr. Growth %	9.54	21.15	6.71	30.31	1.72
Common Equity, 1 Yr. Growth %	19.84	18.43	5.67	310.22	2.7
Cash From Operations, 1 Yr. Growth %	-26	159.78	-99.91	62.1K	67.9
Capital Expenditures, 1 Yr. Growth %	-7.71	-27.16	75.4	88.94	-35.7
Levered Free Cash Flow, 1 Yr. Growth %	-420.95	-231.34	-127.5	935.48	-134.39
Unlevered Free Cash Flow, 1 Yr. Growth %	-400.54	-234.25	-126.31	966.93	-137.71
Compound Annual Growth Rate Over Two Years
Total Revenues, 2 Yr. CAGR %	37.22	30.15	11.14	7.21	24.8
Gross Profit, 2 Yr. CAGR %	36.58	32.12	0.24	-1.66	27.61
EBITDA, 2 Yr. CAGR %	41.21	34.69	-1.06	-3.24	2.08
EBITA, 2 Yr. CAGR %	43.31	36.64	-1.56	-3.57	1.76
EBIT, 2 Yr. CAGR %	49.22	40.84	-5.1	-6.44	-12.81
Earnings From Cont. Operations, 2 Yr. CAGR %	48.79	40.59	0.54	-4.02	-11.21
Net Income, 2 Yr. CAGR %	45.15	38.74	1.92	-3.86	-11.35
Normalized Net Income, 2 Yr. CAGR %	42.58	40.5	-0.99	-5.75	-2.76
Diluted EPS Before Extra, 2 Yr. CAGR %	43.77	38.84	2.05	-2.07	-25.23
Accounts Receivable, 2 Yr. CAGR %	24.52	16.28	13.8	-7.64	-13.44
Inventory, 2 Yr. CAGR %	53.59	37.28	26.64	129.38	111.84
Net Property, Plant and Equip., 2 Yr. CAGR %	3.61	1.44	3.16	13.05	11.17
Total Assets, 2 Yr. CAGR %	19.71	21.25	8.33	87.36	89.04
Tangible Book Value, 2 Yr. CAGR %	9.91	15.19	13.7	17.92	15.66
Common Equity, 2 Yr. CAGR %	15.34	19.13	11.87	108.2	105.26
Cash From Operations, 2 Yr. CAGR %	-1.94	38.65	-95.04	-23.22	3.13K
Capital Expenditures, 2 Yr. CAGR %	4.66	-18.01	13.03	82.05	10.22
Levered Free Cash Flow, 2 Yr. CAGR %	78.36	105.31	-40.37	68.73	91.47
Unlevered Free Cash Flow, 2 Yr. CAGR %	71.04	100.86	-41.02	67.54	103.53
Compound Annual Growth Rate Over Three Years
Total Revenues, 3 Yr. CAGR %	24.9	24.86	26.49	5.58	23.39
Gross Profit, 3 Yr. CAGR %	13.77	26.14	17.69	0.78	15.64
EBITDA, 3 Yr. CAGR %	14.31	29.46	17.74	0.18	-1.7
EBITA, 3 Yr. CAGR %	14.51	30.77	18.43	-0.05	-2.23
EBIT, 3 Yr. CAGR %	12.89	32.86	19.26	-3.22	-12.88
Earnings From Cont. Operations, 3 Yr. CAGR %	11.65	35.88	20.8	0.88	-10.58
Net Income, 3 Yr. CAGR %	12.03	33.1	21.34	1.14	-9.98
Normalized Net Income, 3 Yr. CAGR %	11.11	33.33	18.39	0.6	-6.84
Diluted EPS Before Extra, 3 Yr. CAGR %	10.77	32.45	21.32	2.21	-19.45
Accounts Receivable, 3 Yr. CAGR %	14.77	10.88	25.82	-9.15	3.34
Inventory, 3 Yr. CAGR %	24.43	52.52	26.19	99.28	68.51
Net Property, Plant and Equip., 3 Yr. CAGR %	3.88	2.54	2.93	8.68	9.4
Total Assets, 3 Yr. CAGR %	15.08	17.44	15.14	58.31	54.82
Tangible Book Value, 3 Yr. CAGR %	9.55	13.54	12.29	18.99	12.59
Common Equity, 3 Yr. CAGR %	13.08	16.36	14.46	72.51	64.51
Cash From Operations, 3 Yr. CAGR %	-10.3	35.68	-87.79	15.27	-0.34
Capital Expenditures, 3 Yr. CAGR %	60.6	-7.25	5.65	34.15	28.68
Levered Free Cash Flow, 3 Yr. CAGR %	12.37	61.06	4.5	54.42	0.27
Unlevered Free Cash Flow, 3 Yr. CAGR %	10.71	57.77	1.49	54.82	2.91
Compound Annual Growth Rate Over Five Years
Total Revenues, 5 Yr. CAGR %	25.1	23.31	19.2	17.25	25.81
Gross Profit, 5 Yr. CAGR %	22.74	23.13	8.15	13.81	21.56
EBITDA, 5 Yr. CAGR %	21.21	25.98	7.89	14.92	11.2
EBITA, 5 Yr. CAGR %	21.96	28.1	7.79	15.44	11.46
EBIT, 5 Yr. CAGR %	22.65	27.9	5.32	15.08	5.22
Earnings From Cont. Operations, 5 Yr. CAGR %	27.13	31.87	7.06	17.84	6.8
Net Income, 5 Yr. CAGR %	27.43	29.52	7.87	16.86	7.02
Normalized Net Income, 5 Yr. CAGR %	23.73	26.8	6.1	15.66	9.43
Diluted EPS Before Extra, 5 Yr. CAGR %	25.01	28.55	7.19	17.15	-0.05
Accounts Receivable, 5 Yr. CAGR %	13.59	7.74	14.38	3.06	8.34
Inventory, 5 Yr. CAGR %	10.45	27.59	25.31	79.57	55.25
Net Property, Plant and Equip., 5 Yr. CAGR %	1.06	1.83	3.59	6.62	6.15
Total Assets, 5 Yr. CAGR %	12.81	14.49	12.33	41.57	40.4
Tangible Book Value, 5 Yr. CAGR %	12.38	13.45	11.19	15.27	13.63
Common Equity, 5 Yr. CAGR %	14.32	15	12.59	46.85	44.58
Cash From Operations, 5 Yr. CAGR %	35.23	31.68	-71.82	8.05	13.73
Capital Expenditures, 5 Yr. CAGR %	11.46	34.98	39.55	21.47	7.45
Levered Free Cash Flow, 5 Yr. CAGR %	17.93	77.14	-12.79	63.58	33.14
Unlevered Free Cash Flow, 5 Yr. CAGR %	20.36	66.67	-13.94	61.12	34.06